Photo by nci from unsplash
Approximately 8%–10% of pancreatic ductal adenocarcinoma cases are KRAS wild type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that… Click to show full abstract
Approximately 8%–10% of pancreatic ductal adenocarcinoma cases are KRAS wild type. In a subset of these tumors, NRG1 gene fusions have been identified as targetable oncogenic drivers, a discovery that highlights the importance of deep molecular characterization for KRAS wild-type pancreatic cancers and provides a novel treatment strategy in this disease. See related article by Jones et al., p. 4674
Keywords:
hope targeted;
nrg1 fusions;
cancer;
fusions new;
oncogenic nrg1;
new hope
Journal Title: Clinical Cancer Research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Clinical Cancer Research
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!